Get the Stockscreener App
1.17
0.85%
-0.01
After Hours:
1.14
-0.03
-2.56%
Rein Therapeutics Inc stock is traded at $1.17, with a volume of 23,905.
It is down -0.85% in the last 24 hours and up +1.74% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
23,905
Relative Volume:
0.12
Market Cap:
$30.76M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.63%
1M Performance:
+1.74%
6M Performance:
-0.85%
1Y Performance:
-49.13%
1-Day Range:
$1.14
$1.185
1-Week Range:
$1.10
$1.218
52-Week Range:
$1.02
$2.96
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.17 | 31.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - The Manila Times
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire
Buy Signal: What is Sotera Health Companys valuation compared to sectorJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
Rein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20 - Nasdaq
Aug Sentiment: Is Rein Therapeutics Inc a speculative investmentJuly 2025 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
KDA Group (CVE:KDA) Stock Price Up 23.5% – Still a Buy? - Defense World
Rein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Up 76.0% in January - Defense World
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Jones Trading initiates coverage on Rein Therapeutics stock with Buy rating - Investing.com Canada
Introducing Rein Security: Bringing Production Context to Application Security - Yahoo Finance
Smart Money: Can ASAN sustain earnings growthJuly 2025 Action & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Buy Signal: Is Rein Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Rally Mode: What is the target price for Inno Holdings Inc stockBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
Inhaled IPF therapy LTI-03 awarded orphan drug status in Europe - Pulmonary Fibrosis News
RNTX: Analyst Downgrade by Brookline Capital to 'Hold' | RNTX St - GuruFocus
Brookline Capital Downgrades Rein Therapeutics(RNTX.US) to Hold Rating - 富途牛牛
Rein Therapeutics receives EMA orphan drug designation for IPF treatment By Investing.com - Investing.com Canada
Effort to rein in Wall Street landlords could push US home prices up, investors say - Yahoo Finance
Growth Report: Should I invest in LGCY before earningsTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis - The Manila Times
NN, Inc. Appoints Ted White to Board of Directors - manilatimes.net
Corteva Agriscience Unveils Telbek™ PRO: First Group 21 Fungicide in Cereals, Tackling Fusarium Head Blight for Canadian Wheat Growers - The Manila Times
Titan Aviation Leasing Acquires Boeing 777-300ER to Support China Airlines’ Long-Haul Growth - The Manila Times
Fusemachines Announces Additional Investment by Existing Investor to Support Product Expansion and Client Growth - manilatimes.net
Rein Therapeutics Receives Orphan Drug Designation from - GlobeNewswire
Form 8-KMaterial Events - Stock Titan
Can Rein Therapeutics Inc. stock beat market expectations this quarterSector Performance Drivers & Maximum Profit Growth - bollywoodhelpline.com
Rein Therapeutics Raises Capital via Private Note Offering - TipRanks
Rein Therapeutics Signs Securities Purchase Agreement With Funicular Funds - TradingView
Is Dev Information Technology Limited Forming a Bottom PatternEarnings Forecast Updates & Big Profit Low Trading - bollywoodhelpline.com
Will Rein Therapeutics Inc stock continue dividend increasesWall Street Watch & Safe Entry Trade Signal Reports - Bộ Nội Vụ
Will Krishna Defence and Allied Industries Limited Hold Gains Into CloseDividend Reinvestment Plans & You’ll Thank Yourself in 6 Months - Bollywood Helpline
Stifel Financial (NYSE:SF) Given New $155.00 Price Target at Citizens Jmp - Defense World
Robeco Institutional Asset Management B.V. Has $1.55 Million Position in Diamondback Energy, Inc. $FANG - Defense World
Benjamin Edwards Inc. Reduces Stock Holdings in Roblox Corporation $RBLX - Defense World
Buybacks Report: Will Rein Therapeutics Inc stock attract ESG investorsRisk Management & Fast Exit and Entry Trade Guides - Bộ Nội Vụ
Will Rein Therapeutics Inc. stock attract ESG investorsJuly 2025 Rallies & Low Drawdown Trading Techniques - Улправда
Silly Monks Entertainment Limited Attempts Reversal From Key SupportRisk Adjusted Returns & Free Unlock Portfolio Growth - bollywoodhelpline.com
What sentiment indicators say about Five Below Inc. stock2025 Geopolitical Influence & Safe Entry Point Alerts - Улправда
Can The ODP Corporation stock sustain market leadershipAnalyst Upgrade & Entry Point Confirmation Alerts - Улправда
Is GOOS stock safe for conservative investorsJuly 2025 Update & Safe Capital Growth Stock Tips - Улправда
Fibonacci Levels Suggest Recovery for Narbada Gems and Jewellery LimitedMarket Depth Overview & Build Diversified Portfolios With Ease - bollywoodhelpline.com
Is Rein Therapeutics Inc. stock ready for breakoutJuly 2025 Drop Watch & Smart Allocation Stock Tips - Улправда
Will CIG stock enhance shareholder valueWeekly Stock Report & AI Optimized Trading Strategy Guides - Улправда
Can Centurion Acquisition Corp. Debt Equity Composite Units stock rebound after recent weakness2025 Geopolitical Influence & AI Forecasted Stock Moves - Улправда
What valuation multiples suggest for HAYW stockWeekly Risk Summary & Consistent Growth Equity Picks - Улправда
How SKY Perfect JSAT Holdings Inc. (SKM) stock trades after rate cutsJuly 2025 Trends & Risk Managed Trade Strategies - Улправда
Is VFSWW stock vulnerable to regulatory risksPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
ulpravda ru > 2026> Will BDCX stock benefit from sector rotationRecession Risk & Target Return Focused Stock Picks - ulpravda.ru
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):